43例新型冠状病毒感染流行病学与临床特征分析

doi:10.19871/j.cnki.xfcrbzz.2021.02.010

新发传染病电子杂志 ›› 2021, Vol. 6 ›› Issue (2): 119-124.doi: 10.19871/j.cnki.xfcrbzz.2021.02.010

43例新型冠状病毒感染流行病学与临床特征分析

刘星¹, 刘洪艳², 谷野², 王磊石², 田霞³, 于红⁴, 侯春阳⁵, 李欣悦¹, 宋冠男¹, 王岩¹

1.沈阳市第六人民医院科教科,沈阳 110006;
2.沈阳市第六人民医院辽宁省突发公共卫生事件应急救治专业技术创新中心,沈阳 110006;
3.沈阳市第六人民医院中医康复科,沈阳 110006;
4.沈阳市第六人民医院中医肝病科,沈阳 110006;
5.沈阳市第六人民医院感染科,沈阳 110006

收稿日期:2021-02-03 出版日期:2021-05-31 发布日期:2021-06-24
通讯作者: 王岩,E-mail: professor_wangyan@163.com
基金资助:
1.辽宁省突发公共卫生事件应急救治专业技术创新中心研究基金资助项目; 2.沈阳市科技计划项目（YJ2020-9-010）

The epidemiology and clinical features of 43 cases with novel coronavirus infection

Liu Xing¹, Liu Hongyan², Gu Ye², Wang Leishi², Tian Xia³, Yu Hong⁴, Hou Chunyang⁵, Li Xinyue¹, Song Guannan¹, Wang Yan¹

1. Science and Education Department, the Sixth People's Hospital of Shenyang, Shenyang 110006, China;
2. Professional Technology Innovation Center of Liaoning Public Health Emergency, the Sixth People's Hospital of Shenyang, Shenyang 110006, China;
3. Rehabilitation Department of Traditional Chinese Medicine, the Sixth People's Hospital of Shenyang, Shenyang 110006, China;
4. Department of Chinese Medical Hepatology, the Sixth People's Hospital of Shenyang, Shenyang 110006, China;
5. Infection Department, the Sixth People's Hospital of Shenyang, Shenyang 110006, China

Received:2021-02-03 Online:2021-05-31 Published:2021-06-24

摘要/Abstract

摘要： 目的分析沈阳市新型冠状病毒感染肺炎患者的流行病学及临床特征,为新型冠状病毒肺炎的诊治提供指导。方法收集和分析2020年12月23日至2021年1月26日沈阳市第六人民医院收治的43例确诊新型冠状病毒感染患者的临床资料和治疗情况。结果 43例患者中男性14例,女性29例,年龄范围为16~95岁,平均（54.47±17.97）岁;51.2%的患者有基础疾病;86.0%的患者与确诊患者有接触史;潜伏期3~17d;临床表现主要以发热和上呼吸道症状为主,肺部CT多表现为磨玻璃影。重型/危重型患者实验室检查多表现为白细胞计数、C反应蛋白、D二聚体、白介素-6、降钙素原升高,淋巴细胞计数降低。结论沈阳市确诊的新型冠状病毒感染患者具有年龄偏大、既往基础疾病较多、潜伏期相对较长、重型/危重型患者比例较高、危重患者发展迅速等特点。与轻型/普通型患者相比,重型/危重型患者更易并发肝功能、肾功能、凝血功能异常,心肌损害、心肺功能受损以及感染倾向。

关键词: 冠状病毒, 新型冠状病毒肺炎, 流行病学, 临床特征

Abstract: Objective To analyze the epidemiological and clinical characteristics of the second wave of patients with coronavirus disease 2019 (COVID-19) in Shenyang, and to provide guidance for the diagnosis and treatment of COVID-19. Methods The epidemiological and clinical characteristics of 43 patients with COVID-19 were collected and analyzed from December 23, 2020 to January 26, 2021 in the Sixth People's Hospital of Shenyang. Results Among the 43 patients, there were 14 males and 29 females, with an average age of （54.47±17.97） years old ranging from 16 to 95 years old; 51.2% patients had basic diseases; 86% patients had contact history with confirmed patients; the incubation period was 3 to 17 days; the main clinical manifestations of patients were fever and upper respiratory tract symptoms, and the main pulmonary CT manifestation was ground glass opacity. The laboratory examination of severe/critical patients showed that the number of leukocytes, C-reactive protein, D-dimer, interleukin-6 and procalcitonin were increased, and the number of lymphocytes was decreased. Conclusions The epidemic situation in Shenyang has the characteristics of older patients, more previous basic diseases, longer incubation period, higher proportion of severe/critical patients, and rapid disease progression. Compared with mild/common patients, severe/critical patients were more likely to suffer the infection and the damage in liver, kidney, coagulation, myocardium and cardiopulmonary function.

Key words: Coronavirus, Coranavirus disease 2019, Epidemiology, Clinical characteristics

刘星, 刘洪艳, 谷野, 王磊石, 田霞, 于红, 侯春阳, 李欣悦, 宋冠男, 王岩. 43例新型冠状病毒感染流行病学与临床特征分析[J]. 新发传染病电子杂志, 2021, 6(2): 119-124.

Liu Xing, Liu Hongyan, Gu Ye, Wang Leishi, Tian Xia, Yu Hong, Hou Chunyang, Li Xinyue, Song Guannan, Wang Yan. The epidemiology and clinical features of 43 cases with novel coronavirus infection[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(2): 119-124.

参考文献

[1] HU B, GUO H, ZHOU P, et al.Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021,19(3):141-154.
[2] ASSELAH T, DURANTEL D, PASMANT E,et al.COVID-19: Discovery, diagnostics and drug development[J]. J Hepatol, 2021, 74(1):168-184.
[3] 李倩,卢洪洲. 新型冠状病毒疫苗研究最新进展[J/CD]. 新发传染病电子杂志,2020,5(4):268-273.
[4] 丁金立,章礽荫. 新型冠状病毒肺炎放射检查方案与感染防控专家共识(试行第一版)[J/CD]. 新发传染病电子杂志,2020,5(2):65-73.
[5] 国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版)新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL][2021-01-07]. http://www.nhc.gov.cn/cms-search/downFiles/a449a3e2e2c94d9a856d5faea2ff0f94.pdf.
[6] BRANDON MH, MARIA HSDO, STEFANIE B, et al.Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis[J]. Clin Chem Lab Med, 2020, 58(7):1021-1028.
[7] HE ZP, ZHAO CH, DONG QM, et al.Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets[J]. Int J Infect Dis, 2005, 9(6):323-30.
[8] BRANDON MH.COVID-19, ECMO, and lymphopenia: a word of caution[J]. Lancet Respir Med, 2020,8(4):e24.
[9] HASAN KS, MANDEEP RM.COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal[J]. J Heart Lung Transplant, 2020, 39(5): 405-407.
[10] ZHANG W, ZHAO Y, ZHANG FC, et al.The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China[J]. Clin Immunol, 2020, 214: 108393.
[11] IAN H, RAYMOND P, MICHAEL AL, et al.C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis[J]. Ther Adv Respir Dis, 2020,14:1753466620937175.
[12] LIN L, LU LF, CAO W, et al.Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia[J]. Emerg Microbes Infect, 2020, 9(1):727-732.
[13] FATTORI E, CAPPELLETTI M, COSTA P, et al.Defective inflammatory response in interleukin 6-deficient mice[J]. J Exp Med, 1994, 180(4):1243-1250.
[14] HAN H, MA QF, LI C, et al.Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors[J]. Emerg Microbes Infect, 2020, 9(1):1123-1130.
[15] STUBER F, WRIGGE H, SCHROEDER S, et al.Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury[J]. Intensive Care Med, 2002, 28(7):834-841.
[16] POLLY EP, MARK DE, THOMPSONBT, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury[J]. Crit Care Med, 2005, 33(1):1-6.
[17] LV YL, CHEN LK, LIANG XL, et al. Association between iron status and the risk of adverse outcomes in COVID-19[J]. Clin Nutr, 2020, S0261-5614(20):30654-3.
[18] TANG XP, FANG MQ, CHENG RM, et al.Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability[J]. Circ Res, 2020,127(5):651-663.
[19] HAL D, ANDREW MP.Hepcidin and the iron-infection axis[J]. Science, 2012, 338(6108): 768-772.
[20] INÊS S, TERESA P, SEBASTIAN M. IL-1 beta-mediated macrophagehepatocyte crosstalk upregulates hepcidin under physiological low oxygen levels[J]. Redox Biol, 2019,24:101209.
[21] XIONG SG, SHE HY, HEIGO T, et al.Signaling role of intracellular iron in NF-kappaB activation[J]. J Biol Chem, 2003,278(20):17646-54.
[22] JOHN BM, CARL HJ.Cytokine release syndrome in severe COVID-19[[J]. Science, 2020, 368(6490): 473-474.
[23] BEAT M, STEPHAN H, DAIANA S, et al.Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis, 2007,7:10.
[24] JENNIE H, TIMOTHY G, CRAIG W.Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19[J]. Clin Med (Lond), 2020, 20(3):47.
[25] MÜLLER B, BECKER K, SCHÄCHINGER H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit[J]. Crit Care Med, 2000, 28:977-983.
[26] 宋玉燕,黄长先,周璐,等. 中西医结合疗法治疗31例重型新型冠状病毒肺炎临床疗效分析[J/CD]. 新发传染病电子杂志,2020,5(4):239-242.
[27] EVAN MB, SHMUEL S, ARTURO C, et al.Deployment of convalescent plasma for the prevention and treatment of COVID-19[J]. J Clin Invest, 2020, 30(6):2757-2765.
[28] KARTHICK R, NARAYANASAMY K, JAYANTHI R, et al.Convalescent plasma transfusion for the treatment of COVID-19: Systematic review[J]. J Med Virol. 2020,92(9):1475-1483.
[29] LIN HY.The severe COVID-19: A sepsis induced by viral infection? And its immunomodulatory therapy[J]. Chin J Traumatol, 2020, 23(4):190-195.
[30] LUIGINA R, FRANCESCO B, CLAUDIA M, et al.Thymosina1: an endogenous regulator of inflammation, immunity, and tolerance[J]. Ann NY Acad Sci, 2017,1112:326-338.
[31] OHTAY, SUEKI K,YONEYAMA Y, et al.Immunomodulating activity of thymosin fraction 5 and thymosin Alpha 1 in immunosuppressed mice[J]. Cancer Immunol Immunother, 1983,15(2):108-13.
[32] MITCHELL H.Perspectives on the development of neutralizing antibodies against SARS-CoV-2[J]. Antib Ther, 2020, 3(2): 109-114.
[33] MUTHIAH V, ORLY V, THOMAS M, et al.Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19[J]. N Engl J Med, 382(17): 1653-1659.
[34] YAN RH, ZHANG YY, LI YN, et al.Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2[J]. Science, 367(6485): 1444-1448.
[35] YANG LF, LIU WH, YU X, et al.COVID-19 Antibody Therapeutics Tracker: A Global Online Database of Antibody Therapeutics for the Prevention and Treatment of COVID-19[J]. Antib Ther, 2020,3(3): 205-212.

43例新型冠状病毒感染流行病学与临床特征分析

The epidemiology and clinical features of 43 cases with novel coronavirus infection

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨钟平, 秦圆圆, 周怡宏, 陈耀凯. 新型冠状病毒肺炎合并HIV感染的临床特征及预后的系统文献分析[J]. 新发传染病电子杂志, 2021, 6(2): 113-118.
[2]	邵蔚, 张立, 陈艳, 黄英, 王文慧, 张利君, 沙莉. 医疗失效模式与效应分析在新型冠状病毒肺炎医院感染防控中的应用效果[J]. 新发传染病电子杂志, 2021, 6(2): 129-132.
[3]	李仕康, 李卓, 徐瑞卿, 严晓峰, 李建华, 吕亮, 宋玉燕, 孙强中, 李同心, 钱斓兰, 张英. 基于多模态深度学习的新型冠状病毒肺炎重症转化风险预测[J]. 新发传染病电子杂志, 2021, 6(2): 133-137.
[4]	黄斌, 高波. 新型冠状病毒肺炎对神经系统的影响[J]. 新发传染病电子杂志, 2021, 6(2): 155-159.
[5]	蔡侃儒, 张洁云, 彭亚柏, 程文兵, 张明霞. 两种新型冠状病毒核酸试剂检测结果的对比研究[J]. 新发传染病电子杂志, 2021, 6(1): 18-21.
[6]	蓝博文, 唐润辉, 张志艳, 陈康胤. 多层螺旋CT像素指数定量分析在新型冠状病毒肺炎评估中的应用价值研究[J]. 新发传染病电子杂志, 2021, 6(1): 22-26.
[7]	吕秋莹, 梅树江, 张仁利, 吴永胜, 何建凡, 李媛, 彭博, 张振, 逯建华, 高玮, 房师松, 王敬忠, 温莹, 程聪, 邹旋, 夏俊杰, 彭朝琼, 冯铁建. 新型冠状病毒肺炎精准防控体系构建与效果评价[J]. 新发传染病电子杂志, 2020, 5(4): 229-233.
[8]	宋玉燕, 黄长先, 周璐, 张英, 张安, 詹柱, 李群堂, 邱敏. 中西医结合疗法治疗31例重型新型冠状病毒肺炎临床疗效分析[J]. 新发传染病电子杂志, 2020, 5(4): 239-242.
[9]	李倩, 卢洪洲. 新型冠状病毒疫苗研究最新进展[J]. 新发传染病电子杂志, 2020, 5(4): 268-273.
[10]	任坦坦, 陆普选, 邓国防, 付亮, 张培泽. 2020 WHO全球结核报告:全球与中国关键数据分析[J]. 新发传染病电子杂志, 2020, 5(4): 280-284.
[11]	林绿, 刘夏, 吴念宁, 邹俊, 蓝健, 黄金萍, 陈薪宇, 黄妹青. 血清心肌损伤指标变化与新型冠状病毒肺炎重症风险的相关性研究[J]. 新发传染病电子杂志, 2020, 5(3): 159-164.
[12]	李莎, 卢亦波, 谢周华. 广西地区恙虫病77例临床特征分析[J]. 新发传染病电子杂志, 2020, 5(3): 173-177.
[13]	朱芸仙, 刘静, 任砚, 吴敏昱, 任荣, 朱怡, 姚文妍, 李敏. 新型冠状病毒肺炎核酸检测阳转阴前后CT影像对比[J]. 新发传染病电子杂志, 2020, 5(3): 183-187.
[14]	吴锋耀, 蒙婞婞, 韦彩云, 刘冬梅. 传染病医院新型冠状病毒肺炎疫情防控与职业健康长效机制建设[J]. 新发传染病电子杂志, 2020, 5(3): 198-202.
[15]	. 新型冠状病毒肺炎放射检查方案与感染防控专家共识（试行第一版）[J]. 新发传染病电子杂志, 2020, 5(2): 65-73.